The US Food and Drug Administration (FDA) has approved speciality pharmaceutical company Shorla Oncology’s new drug application (NDA) for TEPYLUTE, a new formulation to treat breast and ovarian cancer.

TEPYLUTE is the third drug in the company’s portfolio to obtain FDA approval, with several other cancer drugs awaiting approval for the US market.

Previously known as SH-105, the asset is a ready-to-dilute, injectable product that simplifies preparation and ensures dosing accuracy for breast and ovarian cancer treatments.

This new liquid formulation of thiotepa, a standard oncology product, removes the requirement for complex reconstitution and supports “just in time” preparation, enhancing consistency in dosing.

Shorla Oncology chief commercial officer Rayna Herman stated: “Among TEPYLUTE’s many benefits, it removes the necessity to reconstitute which can introduce additional risks of drug preparation errors.

“We look forward to providing an update on our launch plans for TEPYLUTE in the near future.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Shorla Oncology is also advancing its portfolio with SH-201, a palatable oral liquid treatment for certain types of leukaemia and other cancers.

The FDA has accepted SH-201 for NDA review in April 2024, with an approval decision anticipated by 30 November.

The company’s pipeline focuses on oncology therapies targeting orphan and paediatric cancers, aiming to address unmet needs, drug shortages and inadequate applications for the intended populations.

Shorla is offering two assets, including Nelarabine, for the treatment of T-cell leukaemia, and JYLAMVO for acute lymphoblastic leukaemia, among other indications.

Shorla Oncology CEO and co-founder Sharon Cunningham said: ‘’This approval fulfils an unmet need by addressing the shortcomings and handling complexities of the current lyophilised powder formulation.

 “We have taken a vital oncology drug and made it easier for oncology clinics and hospitals to use, while also reducing medical personnel exposure to a hazardous drug.”